Brinzolamide


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : Ophth Open-angle glaucoma; Ocular HTN As 1% susp: Instill 1 drop 2-3 times/day, either alone or as adjunctive therapy w/ a topical β-blocker or prostaglandin analogue.
Dosage Details
Ophthalmic
Ocular hypertension, Open-angle glaucoma
Adult: As 1% susp: Instill 1 drop 2-3 times daily, either alone or as adjunctive therapy w/ a topical β-blocker or prostaglandin analogue.
Elderly: No dosage adjustment necessary.
Contraindications
Hypersensitivity to brinzolamide, sulfonamides. Hyperchloraemic acidosis.
Special Precautions
Patient w/ low endothelial cell count. Hepatic and severe renal (CrCl <30 mL/min) impairment. Pregnancy and lactation.
Adverse Reactions
Blurred vision, taste abnormality (bitter, sour, or unusual taste), blepharitis, dermatitis, dry eye, foreign body sensation, headache, hyperaemia, ocular discharge, ocular discomfort, ocular keratitis, ocular pain, ocular pruritus, and rhinitis.
Potentially Fatal: Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anaemia, and other blood dyscrasias.
Patient Counseling Information
This drug may cause temporary blurred vision or other visual disturbances, if affected do not drive or operate machinery.
MonitoringParameters
Monitor intraocular pressure.
Drug Interactions
Concurrent use w/ oral carbonic anhydrase inhibitors may lead to additive systemic effects. Concurrent use w/ high-dose salicylates may lead to toxicity.
Action
Description: Brinzolamide is a carbonic anhydrase inhibitor that decreases secretion of aqueous humour thus reducing intraocular pressure.
Pharmacokinetics:
Absorption: Absorbed into systemic circulation.
Distribution: Brinzolamide and metabolites: Accumulates in RBCs and bind to carbonic anhydrase. Plasma protein binding: Approx 60%.
Metabolism: Metabolised to N-desethyl brinzolamide.
Excretion: Via urine as unchanged drug and metabolites.
Chemical Structure

Chemical Structure Image
Brinzolamide

Source: National Center for Biotechnology Information. PubChem Database. Brinzolamide, CID=68844, https://pubchem.ncbi.nlm.nih.gov/compound/Brinzolamide (accessed on Jan. 21, 2020)

Storage
Store between 4-30°C.
References
Anon. Brinzolamide. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 01/10/2014.

Azopt Suspension (Alcon Laboratories, Inc). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 01/10/2014.

Buckingham R (ed). Brinzolamide. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 01/10/2014.

McEvoy GK, Snow EK, Miller J et al (eds). Brinzolamide (EENT). AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 01/10/2014.

Disclaimer: This information is independently developed by MIMS based on Brinzolamide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
  • Azopt
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in